Is Harmony Biosciences Holdings (HRMY) Cheap Following Reaffirmed 2026 Guidance And A CFO Change?
Event overview and why Harmony Biosciences stock is in focus
Harmony Biosciences Holdings (HRMY) is back in focus after reiterating its 2026 net product revenue guidance of US$1.0b to US$1.04b, alongside a chief financial officer transition and an upcoming second quarter earnings release.
See our latest analysis for Harmony Biosciences Holdings.
The latest guidance confirmation, CFO transition and upcoming earnings date have come alongside a sharp swing in sentiment. The 1 day share price return of 9.97% and the 90 day share price return of 15.23% contrast with a year to date share price return that is slightly down 1.44%, while the 5 year total shareholder return of 43.46% points to a much stronger longer term picture.
If Harmony Biosciences has caught your attention, it can be useful to see what else is moving in related areas, including rare disease and biotech. A good next step is to scan opportunities in higher growth healthcare and biotech using the 39 healthcare AI stocks
For Harmony Biosciences, this sharp move after reaffirming 2026 revenue guidance and announcing a CFO change could signal renewed confidence in the business, or a swing in sentiment that outran fundamentals. So how does the valuation stack up?
Most Popular Narrative: 22.1% Undervalued
With Harmony Biosciences trading at $36.84 against a most popular narrative fair value of $47.30, the valuation gap is drawing fresh attention to the long term story.
The large and growing patient populations affected by sleep disorders and rare neurodevelopmental conditions driven by demographic aging and increased recognition/diagnosis are expanding Harmony's total addressable market, supporting sustained long term revenue growth for both existing and pipeline products.
Want to see what sits behind that revenue ambition for Harmony Biosciences? The narrative leans on rising earnings, wider margins and a future earnings multiple that may surprise you.
Result: Fair Value of $47.30 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Harmony Biosciences still faces key overhangs, with Wakix concentration and the risk of earlier than expected generic entry both capable of frustrating that undervaluation narrative.
Find out about the key risks to this Harmony Biosciences Holdings narrative.
Next Steps
If the mix of caution and optimism around Harmony Biosciences feels familiar, use it as a prompt to review the data yourself, weigh the risks, and see why some investors are focused on its 3 key rewards.
Looking for more investment ideas beyond Harmony Biosciences?
If Harmony Biosciences has sharpened your focus, do not stop there. Fresh ideas across sectors can sharpen your portfolio and keep you ready for the next move.
- Spot potential turnaround stories early by scanning 21 elite penny stocks with strong financials that already show stronger financial footing than many expect from low priced stocks.
- Zero in on quality at a discount by reviewing the 50 high quality undervalued stocks and seeing which companies combine solid fundamentals with pricing that looks appealing.
- Strengthen your defensive side by checking the 9 dividend fortresses for companies offering higher yields supported by resilient cash flows.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com